Kalli C. Catcott
www.linkedin.com
0000-0003-1941-0678
Mersana Therapeutics Inc
4 papers found
Refreshing results…
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
Cover Picture: Identifying Unknown Enzyme-Substrate Pairs from the Cellular Milieu with Native Mass Spectrometry (ChemBioChem 7/2017)
Identifying Unknown Enzyme-Substrate Pairs from the Cellular Milieu with Native Mass Spectrometry
Abstract 2974: Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer
Missing publications? Search for publications with a matching author name.